TrialAdvances in therapy2020

A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies.

Seiichiro Mitani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.